Lilly letter regarding bamlanivimab

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

2 posts / 0 new
Log in or register to post comments
Last post
Sat, 12/05/2020 - 10:16
#1
Mike Cohen
Mike Cohen's picture
Offline
Last seen: 3 months 5 days ago
Joined: 06/08/2014 - 19:54
Lilly letter regarding bamlanivimab

Colleagues:

As a courtesy to Eli Lilly and Company, as directed by the FDA, ISMP is emailing you to notify you of a bamlanivimab Dear HCP letter containing the following message:

"Refer only to the FDA Authorized Fact Sheet for bamlanivimab for preparation and administration instructions and disregard a document entitled “Bamlanivimab Alternative Preparation and Administration Information.”

Please see the attached letter to review the Dear HCP letter.

Mike

Michael R. Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP
President, Institute for Safe Medication Practices
200 Lakeside Drive, Suite 200
Horsham, PA 19044
e-mail: mcohen@ismp.org
web: www.ismp.org
tel: 215 947 7797

Attach files :
PDF icon dear_hcp_letter_-_preparation_and_administration_of_bamlanivimab.pdf

Tags: 

Top